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Abstract Background Lactoferrin is the major antimicrobial protein in human milk. In our
randomized controlled trial (RCT) of bovine lactoferrin (BLF) supplementation in
preterm neonates, BLF reduced late-onset sepsis (LOS). Mother’s own milk (MM)
contains higher concentrations of lactoferrin than donor milk or formula, but whether
BLF is more effective in infants who receive formula or donor milk is uncertain.
Aim To evaluate the incidence of LOS in preterm infants fed MM and in those fed
formula and/or donor milk.
Study Design This is a (A) post hoc subgroup analysis, in our RCTof BLF, of its effects in
preterm infants fed MM, with or without formula, versus those fed formula and/or
donor milk (no-MM) and (B) post hoc meta-analysis, in our RCT of BLF and in the ELFIN
 Paolo Manzoni wrote the first draft of the manuscript.
Copyright © 2019 by Thieme Medical
Publishers, Inc., 333 Seventh Avenue,
New York, NY 10001, USA.
Tel: +1(212) 584-4662.
DOI https://doi.org/
10.1055/s-0039-1691807.
ISSN 0735-1631.
Original ArticleS120
D
ow
nl
oa
de
d 
by
: U
ni
ve
rs
ità
 d
eg
li S
tu
di
 d
i M
ila
no
. C
op
yr
ig
ht
ed
 m
at
er
ia
l.
Lactoferrin (LF) is a bioactive milk protein, with major
immunological, antimicrobial, and gut maturational effects.
Bovine LF (BLF) and human LF have high biochemical homol-
ogy and share the same N-terminal, 11-aminoacidic peptide,
which has antimicrobial antibioticlike properties. Several
randomized controlled trials (RCTs) suggest that BLF supple-
mentation can reduce late-onset sepsis (LOS) in preterm
neonates in NICU.1–6 However, these data are rated as low-
to-moderate quality in a Cochrane review7 and seem to be
inconsistent with a recent RCT in 2,203 preterm infants that
found no effect of BLF supplementation on LOS.8
Human colostrum is rich in LF, with concentrations five-
to sixfold higher than that in mature milk.9 Infants fed since
birth with fresh milk from their mother might therefore
receive adequate quantities of LF. In a case–control study in
97 preterm infants, those who developed LOS had consumed
significantly less breast milk and lower doses of LF and other
milk antimicrobial proteins than the controls.10
In our original RCT of BLF supplementation in preterm
infants,1 we collected nutritional data and reported days of
exposure to, aswell as intakes of, humanmilk, donormilk, and
formula milk for all patients. There were no differences in the
relative proportions of mother’s own milk (MM) fed and
formula/donormilk fed infants between the three randomiza-
tion groups (BLF alone, BLF þ the probiotic Lactobacillus
rhamnosus GG [LGG], placebo). We showed a significant pro-
tective effect of BLF that remained independent of the type of
feeding after multiple logistic regression analysis.
In this exploratory analysis, we evaluated the hypothesis
that lactoferrin may be more effective in reducing LOS in
preterm infants who receive a lower proportion of their own
mother’s milk.
Materials and Methods
(A) This was a secondary analysis of data obtained during a
multicenter RCT performed in Italy and New Zealand from
2006 to 2008; its original protocol is published pre-
viously.1,11 Preterm very low birthweight (VLBW) neonates
from 11 tertiary NICUs were enrolled before 72 hours of life
and were randomly assigned to receive BLF alone (LF100,
Dicofarm SpA, Rome, Italy; 100 mg/day, group A1) or in
combination with LGG (Dicoflor60, Dicofarm SpA, Rome,
Italy; 106 colony-forming units per day, group A2) or placebo
(group B) from birth to DOL 30 (DOL 45 for those<1,000 g at
birth). The drugs and placebo were administered orally once
a day. Neonates not feeding in the first 48 hours received the
drug(s)/placebo by orogastric tube. Results from this RCT
showed that BLF supplementation, alone or in combination
with LGG, reduces the risk of LOS and necrotizing enteroco-
litis1 in VLBW infants compared with placebo.
Per protocol, clinical and management data were col-
lected prospectively for all enrolled infants until death or
discharge. Systematic clinical surveillance for adverse events
was performed through daily infant examination until 2 days
after the end of treatment.
Nutritional and feeding policies were stable during the
study and consistent among centers, following common
guidelines and adherence to the study protocol. In particu-
lar, the use of fresh MM was encouraged; when it was not
available, the neonates were fed either a standard preterm
milk formula, not supplemented with LF,1 and/or with
donor milk obtained through processing (including 62.5°C
Holder pasteurization, followed by refrigeration) of pooled
milk.
Clinical surveillance for the detection of sepsis was per-
formed in all enrolled infants, with complete laboratory and
microbiology evaluation in case of suspected LOS.
In this secondary analysis, the primary aimwas to test the
hypothesis that BLF has a lower impact in reducing LOS in
infantswho receiveMM than in thosewho receive formula or
donor milk.
Standard laboratory methods were used to identify bac-
teria from cultures.12 For Candida species, specimens were
(Enteral Lactoferrin in Neonates) RCT, of the effect of BLF in subgroups not exclusively
fed MM.
Results (A) Of 472 infants in our RCT, 168 were randomized to placebo and 304 were
randomized to BLF. Among MM infants, LOS occurred in 22/133 (16.5%) infants
randomized to placebo and in 14/250 (5.6%) randomized to BLF (relative risk or risk
ratio (RR): 0.34; relative risk reduction (RRR): 0.66; 95% confidence interval (95% CI) for
RR: 0.18–0.64; p < 0.0008). Among no-MM infants, LOS occurred in 7/35 (20.0%)
randomized to placebo and in 2/54 (3.7%) randomized to BLF (RR: 0.19; RRR: 0.81; 95%
CI for RR: 0.16–0.96; p ¼ 0.026). In multivariable logistic regression analysis, there was
no interaction between BLF treatment effect and type of feeding (p ¼ 0.628). (B) In
1,891 infants not exclusively fedMM in our RCTof BLF and in the ELFIN RCT, BLF reduced
the RR of LOS by 18% (RR: 0.82; 95% CI: 0.71–0.96; p ¼ 0.01).
Conclusion Adequately powered studies should address the hypothesis that BLF is
more effective in infants fed formula or donor milk than those fed MM. Such studies
should evaluate whether a specific threshold of total lactoferrin intake can be identified
to protect such patients from LOS.
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incubated on chromogen culture plates (Albicans ID, bioMér-
ieux, Marcy l’Etoile, France) to identify Candida albicans blue
staining colonies after 48 hours of incubation at 37°C.
Colonies were speciated biochemically (Vitec Yeast,
bioMérieux).13
The criteria for hospital discharge were birthweight of
1,800 g, full oral feeding, and resolution of acute medical
conditions. Sepsis episodes were treated with antibiotics/
antifungal agents in accordance with the existing literature,
guidelines from international consensus documents, and the
Italian Neonatology Society’s Fungal Infections Task Force
recommendations.14 Blinding was not broken to guide
therapy.
Infants who received fresh MM, exclusively or with for-
mula or donor milk, were compared with those not exposed
to MM (no-MM, i.e. formula milk and/or donor milk) with
regard to the incidence of the first episode of LOS in patients
receiving or not receiving BLF.
(B)We combined subgroup data in ameta-analysis of data
from our RCT of BLF1 and the ELFIN (Enteral Lactoferrin in
Neonates) RCT8 using RevMan 5.3 software package
(Cochrane).1,15
Statistical Analysis
(A) Randomly allocated groups A1 (BLF) and A2 (BLF þ LGG)
were combined to increase the size of the BLF comparator
group. We created a binary variable with a value of 1 if the
infant received MM, exclusively or with formula, and with a
value of 0 if the infant did not receive MM.
In univariable analyses, relative risks (RRs, i.e., risk ratios)
and 95% confidence intervals (CIs) were calculated to com-
pare the cumulative between-group incidence of all infec-
tions, in subgroups according to infants who received MM
and those who did not.
We also undertook multivariable logistic regression ana-
lysis in the whole cohort to explore whether MM modifies
the effect of BLF treatment (and hence if stratification by type
of feeding is needed). We derived odds ratios and 95% CIs
after fitting a multilevel (random-intercept) logistic regres-
sion model similar to that presented in ►Table 1 of our
original paper. We replaced the original variable represent-
ing the type of feeding with the new dichotomous one (MM
versus no-MM) and calculated a likelihood ratio statistic to
detect any interaction between treatment and type of
feeding.
(B) We calculated risk ratios (i.e., RRs) and 95% CIs for
the effect of BLF on LOS in a post hoc, subgroup meta-
analysis in the twoRCTs usingfixed effectsmodels in RevMan
5.3.16
Results
(A) Complete data for analysis were available for 472 infants.
Among them, 383 were fed MM, either exclusively or with
formula, and 89 were fed formula or donor milk (72 formula,
17 donormilk). A Consort flowchart of enrolled and analyzed
patients is shown in ►Fig. 1.
The main results are summarized in ►Tables 1 to 6>. As
expected, the incidence of LOS was less frequent in MM
infants than in no-MM infants. LOS occurred in 22 infants
who were fed MM, 7 infants who were not fed MM and who
received placebo, and 16 of those who received BLF (14 MM
and 2 no MM).
The point estimate for the RR of LOS in infants receiving
MMalone (in the absence of treatment with LF) is close to 1.0
(OR ¼ 0.91), with large CIs (0.21–3.96). (►Table 6).
When we stratified the analysis for type of feeding
in univariable analyses, the point estimate for the RR of
LOS after BLF treatment in infants receiving MM (RR: 0.34;
95% CI: 0.18–0.64) was almost double than that of those
infants not receiving MM (RR: 0.19; 95% CI: 0.04–0.84)
(►Tables 1–4).
In the multivariable logistic regression model, the point
estimate for the odds of LOS associated with BLF treatment
was more than doubled in infants who received MM (OR:
0.38 for BLF and 0.22 for BLF þ LGG vs. placebo) than those
who did not (OR: 0.12 for BLF and 0.15 for BLF þ LGG vs.
placebo). However, the introduction of an interaction term
between type of feeding and treatment did not improve the
model fit significantly (likelihood ratio test p-value: 0.628),
indicating no significant interaction (►Tables 5 and 6).
(B) In 1,891 infants not exclusively fed MM in our RCT1 of
BLF and in the ELFIN RCT8, BLF reduced the RR of LOS by 18%
(RR: 0.82; 95% CI: 0.71–0.96; p ¼ 0.01) (►Fig. 2).When cases
of fungal sepsis were excluded from the analysis, the RR for
LOS after BLF treatment was 0.85 (95% CI: 0.73–0.99;
p ¼ 0.04).
Discussion
Our hypothesis was that receivingMMmay reduce the effect
of BLF on LOS. In analysis A, univariable analyses are con-
sistent with this hypothesis, but multivariable logistic
regression analysis does not confirm it as there was no
significant interaction between feeding type and BLF treat-
ment. In analysis B, there was evidence that BLF may reduce
LOS in infants not exclusively receiving MM.
Our results are therefore consistent with data showing
that human milk has a protective effect against infection15
Table 1 Univariable analysis of BLF and LOS in infants receiving mother’s own milk: BLF treatments combined versus placebo
Groups (total n ¼ 383) A1 þ A2 vs. B
BLF þ LGG (A1 þ A2),
n ¼ 250
Placebo (B),
n ¼ 133
RR 95% CI p-Value
Total LOS (n ¼ 36) 14/250
(5.6%)
22/133
(16.5%)
0.34 0.18–0.64 0.0008
Abbreviations: BLF, bovine lactoferrin; CI, confidence interval; LGG, Lactobacillus rhamnosus GG; LOS, late-onset sepsis; RR, relative risk.
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Screened and assessed 
for eligibility  (n = 494)
Excluded (n = 22)
• Incomplete data on type of 
feeding (n = 22 )
Analyzed (n = 304)
(n = 153 in A1; n = 151 in A2)
Exposed to mother’s own milk 
(127 in A1; 123 in A2; 
Total = 250)
Not exposed to mother’s own 
milk (26 in A1; 28 in A2; 
Total = 54)
Allocated to BLF
(n = 304: n = 153 in A1; n = 151 in A2)
Received allocated intervention
(n = 304: n = 153 in A1; n = 151 in A2)
Did not receive allocated intervention
(n = 0)   
Exposed to mother’s own milk
(n = 133)
Not exposed to mother’s own 
milk (n = 35)
Allocated to PLACEBO
(n = 168)
Received placebo
(n = 168)
Did not receive placebo
(n = 0)
Analyzed (n = 168)
Allocation
Analysis
Follow-Up
Enrollment
Is it randomized?
Fig. 1 CONSORT (Consolidated Standards of Reporting Trials) e-flowchart.
Table 2 Univariable analysis of BLF and LOS in infants fed MM
Groups (total n ¼ 383) A1 vs. B A2 vs. B
BLF (A1),
n ¼ 127
BLF þ LGG (A2),
n ¼ 123
Placebo
(B), n ¼ 133
RR 95% CI p-Value RR 95% CI p-Value
Total LOS
(n ¼ 36)
8/127
(6.3%)
6/123
(4.9%)
22/133
(16.5%)
0.38 0.17–0.82 0.011 0.29 0.12–0.70 0.004
Abbreviations: BLF, bovine lactoferrin; CI, confidence interval; LOS, late-onset sepsis; MM, mother’s own milk; RR, relative risk.
Table 3 Univariable analysis of BLF and LOS in infants not fed MM
Groups (total n ¼ 89) A1 vs. B A2 vs. B
BLF (A1),
n ¼ 26
BLF þ LGG (A2),
n ¼ 28
Placebo (B),
n ¼ 35
RR 95% CI p-Value RR 95% CI p-Value
Total LOS
(n ¼ 9)
1/26
(3.8%)
1/28
(3.6%)
7/35
(20.0%)
0.19 0.03–1.47 0.122 0.18 0.02–1.37 0.066
Abbreviations: BLF, bovine lactoferrin; CI, confidence interval; LGG, Lactobacillus rhamnosus GG; LOS, late-onset sepsis; MM, mother’s own milk; RR,
relative risk.
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and that this beneficial effect may be related to cumulative
intake, with intake thresholds that confer significant protec-
tion compared with lower intakes.17 In a retrospective case–
control study, Trend et al showed that infants who experi-
enced LOS were exposed to lower cumulative intakes of
lactoferrin through human milk than controls.10 That study
demonstrated that the average consumption of LF by infants
without LOS was 300 to 800 mg/kg/day, which is much
Table 4 Univariable analysis of BLF and LOS in infants not receiving MM: BLF treatments combined versus placebo
Groups (total n ¼ 89) A1/A2 vs. B
BLF þ LGG (A1 þ A2), n ¼ 54 Placebo (B), n ¼ 35 RR 95% CI p-Value
Total LOS (n ¼ 9) 2/54
(3.7%)
7/35
(20.0%)
0.19 0.04–0.84 0.026
Abbreviations: BLF, bovine lactoferrin; CI, confidence interval; LGG, Lactobacillus rhamnosus GG; LOS, late-onset sepsis; MM, mother’s own milk; RR,
relative risk.
Table 5 Multivariable logistic regression analysis controlling for the most important risk factors possibly associated with LOS
OR 95% CI p-Value
BLF and MM (referent: placebo and formula or donor milk (no-MM) 0.38 0.15 0.96 0.008
BLF þ LGG and MM (referent: placebo and formula or donor milk (no-MM) 0.22 0.08 0.64
Sex (referent: male) 1.85 0.87 3.96 0.112
Gestational age (weeks)a 0.70 0.57 0.88 0.002
Birthweight (grams)a 1.00 1.00 1.00 0.331
Use of H2 blockers (total days)a 1.03 0.99 1.08 0.154
Use of postnatal steroids (total days)a 1.10 0.54 2.22 0.796
Daily average amounts of MM intake (mL/kg) 1.00 0.98 1.01 0.600
Abbreviations: BLF, bovine lactoferrin; CI, confidence interval; LGG, Lactobacillus rhamnosus GG; LOS, late-onset sepsis; MM, mother’s own milk;
OR, odds ratio.
aOR for a one-unit increase.
Table 6 Interaction between type of milk feeding and BLF treatment
OR 95% CI p-Value
Interaction milk and treatment
A1 (referent: placebo) in infants fed no MM 0.12 0.01 1.23 0.094
A2 (referent: placebo) in infants fed no MM 0.15 0.02 1.59
Milk type: maternal (referent: nonmaternal) in infants treated with placebo 0.91 0.21 3.96 0.897
Abbreviations: BLF, bovine lactoferrin; CI, confidence interval; OR, odds ratio.
Note: p-Value of likelihood ratio statistic to detect any interaction between treatment and type of feeding: 0.628. Within-center correlation: 4.2%;
p-value: 0.18.
Fig. 2 Meta-analysis of the effect of bovine lactoferrin on late-onset sepsis in 1,891 preterm infants who were not exclusively fed mother’s own
milk in two RCTs of lactoferrin supplementation. In Fig. 2 of the original ELFIN trial report, the subtotals 10/ 53 and 12/60 in the subgroup analysis
for infants fed formula only were incorrectly transposed between the groups randomized to lactoferrin and control, producing a risk ratio of 1.06
instead of 0.94. This error is corrected in the diagram shown here. CI, confidence interval; ELFIN, Enteral Lactoferrin in Neonates. (Adapted from
ELFIN Trial Investigators Group.8)
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higher (three- to fourfold) than the LF consumed by infants
who had sepsis. In the same study, fresh breast milk samples
and formula were also assessed for their antimicrobial
properties in in vitro experiments. Specific threshold LF
levels consistent with the intakes coming from breast fresh
milk were needed to limit pathogen growth and hence
achieve clinical protection from sepsis.
It is known that colostrum and intermediate milk are rich
in LF compared with mature milk and that this may be even
more true with human milk from mothers of premature
infants.18,19 Our group has calculated that exposure to LF
through humanmilk in awell premature infant could rapidly
increase to some 100 to 150mg/day soon after the first week
of life if the baby tolerates full feedswithMM from soon after
birth.11
Thesefindings suggest that intakes of LF in excess to those
already delivered by MM might not confer an additional
advantage, being in line with the assumption that concen-
trations in colostrum and MM should be naturally tailored
for the needs of the infant. In contrast, LF supplementation
replacing the gap in intakes in those babies not receiving the
correct amounts of MM (as in infants fed formula or fed
donor processed milk) could improve protection from
infections.
These data may help reconcile the inconsistencies
between LF studies in the past 12 years and the UK ELFIN
trial including 2,203 preterm infants, which reported no
reduction in LOS after BLF treatment.8 One reason for the
difference between our earlier trial in 20091 and the ELFIN
trial8may be a reduction in the use of formula only from 15%
in our trial to 5% in ELFIN. The hypothesis that BLF is more
effective in infants not receiving MM could be evaluated
further in an individual participant data meta-analysis of
published studies.
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